Chapter 18 Modeling of Growth Factor-Receptor Systems. From Molecular-Level Protein Interaction Networks to Whole-Body Compartment Models

Methods in Enzymology

Volumn 467, Issue C, 2009, Pages 461-497

  Wu, Florence T H ^a   Stefanini, Marianne O ^a   Gabhann, Feilim Mac ^b   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; GROWTH FACTOR RECEPTOR; ISOPROTEIN; NEUROPILIN 1; VASCULOTROPIN A;

BINDING SITE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; COMPARTMENT MODEL; DIFFUSION; ENDOTHELIUM CELL; GENE THERAPY; GEOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC DRAINAGE; MATHEMATICAL COMPUTING; MUSCLE ISCHEMIA; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SIMULATION; TISSUE OXYGENATION; ANGIOGENESIS; ANIMAL; ARTICLE; AUDIOVISUAL EQUIPMENT; BIOLOGICAL MODEL; COMPUTER SIMULATION; EXTRACELLULAR MATRIX; GENETICS; MATHEMATICS; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; POROSITY; RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; COMPUTER SIMULATION; EXTRACELLULAR MATRIX; GENE THERAPY; HUMANS; MATHEMATICS; MODELS, ANATOMIC; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPILIN-1; OXYGEN CONSUMPTION; POROSITY; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN ISOFORMS; RATS; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71549172503     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(09)67018-X     Document Type: Review

References (67)

1. Andrae J., Gallini R., and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22 (2008) 1276-1312
2. Augustin H.G., Koh G.Y., Thurston G., and Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-tie system. Nat. Rev. Mol. Cell. Biol. 10 (2009) 165-177
3. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9 (2003) 936-943
4. Bao P., Kodra A., Tomic-Canic M., Golinko M.S., Ehrlich H.P., and Brem H. The role of vascular endothelial growth factor in wound healing. J. Surg. Res. 153 (2009) 347-358
5. Beenken A., and Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat. Rev. Drug. Discov. 8 (2009) 235-253
6. Bogaert E., Van Damme P., Poesen K., Dhondt J., Hersmus N., Kiraly D., Scheveneels W., Robberecht W., and Van Den Bosch L. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol. Aging (2009) [Epub ahead of print] Pubmed ID: 19185395
7. Brown M.D., and Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: Involvement of VEGF and metalloproteinases. Angiogenesis 6 (2003) 1-14
8. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2 (2009) re1
9. Collinson D.J., and Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: Can biotechnology produce an effective collateral circulation?. Eur. J. Vasc. Endovasc. Surg. 28 (2004) 9-23
10. Ebos J.M., Bocci G., Man S., Thorpe P.E., Hicklin D.J., Zhou D., Jia X., and Kerbel R.S. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res. 2 (2004) 315-326
11. Feng D., Nagy J.A., Dvorak H.F., and Dvorak A.M. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc. Res. Tech. 57 (2002) 289-326
12. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
13. Filion R.J., and Popel A.S. A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann. Biomed. Eng. 32 (2004) 645-663
14. Filion R.J., and Popel A.S. Intracoronary administration of FGF-2: A computational model of myocardial deposition and retention. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) 263-279
15. Forsten K.E., Fannon M., and Nugent M.A. Potential mechanisms for the regulation of growth factor binding by heparin. J. Theor. Biol. 205 (2000) 215-230
16. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
17. Fu B.M., and Shen S. Structural mechanisms of acute VEGF effect on microvessel permeability. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) 2124-2135
18. Gagnon M.L., Bielenberg D.R., Gechtman Z., Miao H.Q., Takashima S., Soker S., and Klagsbrun M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl. Acad. Sci. USA 97 (2000) 2573-2578
19. Garlick D.G., and Renkin E.M. Transport of large molecules from plasma to interstitial fluid and lymph in dogs. Am. J. Physiol. 219 (1970) 1595-1605
20. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., Hong K., Marsters J.C., and Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
21. Girling J.E., and Rogers P.A. Recent advances in endometrial angiogenesis research. Angiogenesis 8 (2005) 89-99
22. Goldman D., and Popel A.S. A computational study of the effect of capillary network anastomoses and tortuosity on oxygen transport. J. Theor. Biol. 206 (2000) 181-194
23. Gordon M.S., Margolin K., Talpaz M., Sledge Jr. G.W., Holmgren E., Benjamin R., Stalter S., Shak S., and Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19 (2001) 843-850
24. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 4 (2004) 361-370
25. Haigh J.J. Role of VEGF in organogenesis. Organogenesis 4 (2008) 247-256
26. Harper S.J., and Bates D.O. VEGF-A splicing: The key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 8 (2008) 880-887
27. Ji J.W., Tsoukias N.M., Goldman D., and Popel A.S. A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J. Theor. Biol. 241 (2006) 94-9108
28. Ji J.W., Mac Gabhann F., and Popel A.S. Skeletal muscle VEGF gradients in peripheral arterial disease: Simulations of rest and exercise. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3740-H3749
29. Jiang B.H., Semenza G.L., Bauer C., and Marti H.H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 271 (1996) C1172-C1180
30. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 358 (2008) 2039-2049
31. Kut C., Mac Gabhann F., and Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer 97 (2007) 978-985
32. Lauffenburger D.A., and Linderman J.L. Receptors: Models for Binding, Trafficking, and Signaling (1993), Oxford University Press, New York
33. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell. Biol. 169 (2005) 681-691
34. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., and Iruela-Arispe M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130 (2007) 691-703
35. Lee T., Seng S., Sekine M., Hinton C., Fu Y., Avraham H.K., and Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 4 (2007)
36. Lloyd P.G., Prior B.M., Yang H.T., and Terjung R.L. Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1668-H1678
37. Lodish H., Berk A., Matsudaira P., Kaiser C.A., Krieger M., Scott M.P., Zipursky S.L., and Darnell J. Molecular Cell Biology (2004), W.H. Freeman & Co., New York
38. Mac Gabhann F., and Popel A.S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H153-H164
39. Mac Gabhann F., and Popel A.S. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: A computational model. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2851-H2860
40. Mac Gabhann F., and Popel A.S. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput. Biol. 2 (2006) e180
41. Mac Gabhann F., and Popel A.S. Systems biology of vascular endothelial growth factors. Microcirculation 15 (2008) 715-738
42. Mac Gabhann F., Ji J.W., and Popel A.S. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput. Biol. 2 (2006) e127
43. Mac Gabhann F., Ji J.W., and Popel A.S. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann. Biomed. Eng. 35 (2007) 982-994
44. Mac Gabhann F., Ji J.W., and Popel A.S. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J. Appl. Physiol. 102 (2007) 722-734
45. Maharaj A.S., and D'Amore P.A. Roles for VEGF in the adult. Microvasc. Res. 74 (2007) 100-113
46. Martin D., Galisteo R., and Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 284 (2009) 6038-6042
47. Mazitschek R., and Giannis A. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Curr. Opin. Chem. Biol. 8 (2004) 432-441
48. Pollak M. Insulin and insulin-like growth factor signalling in Neoplasia. Nat. Rev. Cancer 8 (2008) 915-928
49. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
50. Pries A.R., and Secomb T.W. Microvascular blood viscosity in vivo and the endothelial surface layer. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2657-H2664
51. Qutub A.A., and Popel A.S. A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 Alpha. J. Cell. Sci. 119 (2006) 3467-3480
52. Qutub A.A., Mac Gabhann F., Karagiannis E.D., Vempati P., and Popel A.S. Multiscale models of angiogenesis. IEEE Eng. Med. Biol. Mag. 28 (2009) 14-31
53. Roy H., Bhardwaj S., and Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 580 (2006) 2879-2887
54. Segerstrom L., Fuchs D., Backman U., Holmquist K., Christofferson R., and Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr. Res. 60 (2006) 576-581
55. Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D., Yagel S., and Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102 (2008) 1566-1574
56. Simons M. Integrative signaling in angiogenesis. Mol. Cell. Biochem. 264 (2004) 99-102
57. Stefanini M.O., Wu F.T.H., Mac Gabhann F., and Popel A.S. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst. Biol. 2 (2008) 77
58. Tang K., Breen E.C., Wagner H., Brutsaert T.D., Gassmann M., and Wagner P.D. HIF and VEGF relationships in response to hypoxia and sciatic nerve stimulation in rat gastrocnemius. Respir. Physiol. Neurobiol. 144 (2004) 71-80
59. Truskey G.A., Yuan F., and Katz D.F. Porosity, tortuosity, and available volume fraction (2004), Transport Phenomena in Biological Systems, Pearson Prentice Hall, NJ pp. 389-398
60. Venturoli D., and Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal Physiol. 288 (2005) 605-613
61. Verheul H.M., Lolkema M.P., Qian D.Z., Hilkes Y.H., Liapi E., Akkerman J.W., Pili R., and Voest E.E. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer Res. 13 (2007) 5341-5347
62. Wijelath E.S., Rahman S., Namekata M., Murray J., Nishimura T., Mostafavi-Pour Z., Patel Y., Suda Y., Humphries M.J., and Sobel M. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: Enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ. Res. 99 (2006) 853-860
63. Wiley H.S., Shvartsman S.Y., and Lauffenburger D.A. Computational modeling of the EGF-receptor system: A paradigm for systems biology. Trends Cell. Biol. 13 (2003) 43-50
64. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23 (2005) 8136-8139
65. Wu F.T., Stefanini M.O., Mac Gabhann F., Kontos C.D., Annex B.H., and Popel A.S. A computational kinetic model of VEGF trapping by soluble VEGF receptor-1: Effects of transendothelial and lymphatic macromolecular transport. Physiol. Genomics 38 (2009) 29-41
66. Wu F.T., Stefanini M.O., Mac Gabhann F., and Popel A.S. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE 4 (2009) e5108
67. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756